Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $428.77M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.76M
Average 0.51M
PRTA Interest Income
Income earned on cash, deposits, and investments held by the company.
Prothena Corporation plcNASDAQ: PRTA
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $2.42M fell 44.4% year over year, ahead of the -46.9% change in trailing-twelve-month interest income. Sequentially, it fell 8.7% from the prior quarter. Over 3 fiscal years it compounded at +30.6% a year.
Context
- Interest income amounted to 146.0% of revenue in FY2025, up 126.9 pp from a year earlier.
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -44.4% holds above the trailing-twelve-month pace of -46.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 14.14M USD
- Year-over-year change
- -45.2%
- 4-year CAGR
- +328.3%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.14M | -45.2% |
| FY2024 | 2024-12-31 | 25.82M | -16.8% |
| FY2023 | 2023-12-31 | 31.01M | +388.5% |
| FY2022 | 2022-12-31 | 6.35M | +15016.7% |
| FY2021 | 2021-12-31 | 42K | — |
Interest Income vs competitors
How PRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -46.9% is the 3rd highest of 8, against a peer median of -52.7%.
- Interest income amounts to 21.1% of revenue for PRTA, versus a peer median of 36.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $132M USD | +53.0% | -0.6% | 1.3% | |
| LTM Jun 2026 | $28.36M USD | -48.1% | +42.7% | 786.9% | |
| LTM Mar 2026 | $12.21M USD | -46.9% | +30.6% | 21.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $6.07M USD | -63.6% | +22.3% | — |
| LTM Mar 2026 | $6.04M USD | -52.7% | +46.0% | — | |
| LTM Dec 2025 | $4.36M USD | -34.9% | +70.3% | — | |
| LTM Mar 2026 | CHF 1.36M CHF | -58.3% | +200.1% | 36.6% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Jun 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | -$1.14M USD | -107.3% | +38.6% | — | |
| Peer median (excluding PRTA) | — | -52.7% | +42.7% | 36.6% | |
Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 200.58M | 53.91M | 91.37M | 135.16M | 9.68M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.7M |
| Gross Profit | 200.58M | 53.91M | 91.37M | 135.16M | 5.98M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 61.8% |
| Research & Development | 82.28M | 135.56M | 220.57M | 222.52M | 134.85M |
| Selling, General & Admin | 46.32M | 49.9M | 61.84M | 67.2M | 59.39M |
| Operating Expenses | 128.6M | 185.46M | 282.41M | 289.72M | 190.54M |
| Depreciation & Amortization | 1.12M | 744K | 928K | 893K | 3.7M |
| EBITDA | 73.04M | (124.86M) | (159.55M) | (128.04M) | (197.13M) |
| EBITDA Margin | 36.4% | -231.6% | -174.6% | -94.7% | -2035.6% |
| Operating Income | 71.98M | (131.56M) | (191.04M) | (154.56M) | (184.56M) |
| Operating Margin | 35.9% | -244.1% | -209.1% | -114.4% | -1905.8% |
| Interest Income | 42K | 6.35M | 31.01M | 25.82M | 14.14M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (54K) | 5.95M | 30.56M | 25.63M | (16.27M) |
| Income Before Tax | 71.92M | (125.61M) | (160.48M) | (128.93M) | (200.83M) |
| Pre-Tax Margin | 35.9% | -233.0% | -175.6% | -95.4% | -2073.8% |
| Income Tax Expense | 4.95M | (8.66M) | (13.45M) | (6.62M) | 43.26M |
| Net Income | 66.98M | (116.95M) | (147.03M) | (122.31M) | (244.09M) |
| Net Margin | 33.4% | -217.0% | -160.9% | -90.5% | -2520.6% |
| EPS (Basic) | 1.51 | (2.47) | (2.76) | (2.27) | (4.53) |
| EPS (Diluted) | 1.38 | (2.47) | (2.76) | (2.27) | (4.53) |
| Weighted Avg Shares | 44.23M | 47.37M | 53.22M | 53.77M | 53.83M |
| Weighted Avg Shares (Diluted) | 48.46M | 47.37M | 53.22M | 53.77M | 53.83M |
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.